MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
series l preferred...
$10,508K
Exercise of warrants and
issuance of inducement...
$5,496K
Net cash provided by
financing activities
$15,775K
Canceled cashflow
$229K
Net increase in cash
and cash...
$2,861K
Canceled cashflow
$12,914K
Payment of dividend on
series l preferred...
$229K
Loss on initial
recognition of greenshoe...
$28,736K
Stock based
compensation
$432K
(increase) decrease in
prepaid expenses and...
-$377K
Issuance of warrants for
vrt waiver
$44K
Net cash used in
operating activities
-$12,914K
Canceled cashflow
$29,589K
Net loss
-$28,354K
Change in fair value of
greenshoe rights...
-$11,413K
Increase (decrease) in
accounts payable and...
-$1,297K
Gain on settlement of
debt
$998K
Change in fair value of
warrant liability
-$241K
Gain on
extinguishment of debt
$200K
Back
Back
Cash Flow
source: myfinsight.com
GT Biopharma, Inc. (GTBP)
GT Biopharma, Inc. (GTBP)